India Globalization Capital Inc - Asset Resilience Ratio

Latest as of September 2025: 11.60%

India Globalization Capital Inc (IGC) has an Asset Resilience Ratio of 11.60% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IGC working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$1.13 Million
Cash + Short-term Investments

Total Assets

$9.74 Million
All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2006–2025)

This chart shows how India Globalization Capital Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of India Globalization Capital Inc.

Liquid Assets Composition Over Time

This chart breaks down India Globalization Capital Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore India Globalization Capital Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $1.10 Million 11.34%
Short-term Investments $25.00K 0.26%
Total Liquid Assets $1.13 Million 11.60%

Asset Resilience Insights

  • Moderate Liquidity: India Globalization Capital Inc has 11.60% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

India Globalization Capital Inc Industry Peers by Asset Resilience Ratio

Compare India Globalization Capital Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
Biotechnology 16.06%
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Revolution Medicines Inc
NASDAQ:RVMD
Biotechnology 72.23%
Abivax SA
PA:ABVX
Biotechnology 2.34%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
SOLENO THERAPEUT. DL-001
F:6XC
Biotechnology 41.74%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 37.31%

Annual Asset Resilience Ratio for India Globalization Capital Inc (2006–2025)

The table below shows the annual Asset Resilience Ratio data for India Globalization Capital Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-03-31 4.63% $405.00K $8.75 Million -7.47pp
2024-03-31 12.10% $1.20 Million $9.90 Million -7.40pp
2023-03-31 19.50% $3.35 Million $17.18 Million -19.48pp
2022-03-31 38.98% $10.46 Million $26.83 Million -1.80pp
2021-03-31 40.78% $14.63 Million $35.87 Million -1.79pp
2020-03-31 42.57% $12.34 Million $28.98 Million -34.00pp
2019-03-31 76.57% $26.39 Million $34.47 Million +59.93pp
2018-03-31 16.65% $1.81 Million $10.85 Million -4.78pp
2017-03-31 21.43% $2.42 Million $11.28 Million +21.34pp
2016-03-31 0.09% $17.17K $18.86 Million -0.15pp
2015-03-31 0.24% $49.54K $20.33 Million +0.04pp
2014-03-31 0.20% $35.69K $17.73 Million +0.11pp
2013-03-31 0.09% $16.85K $19.25 Million --
2012-03-31 0.00% $0.00 $25.26 Million --
2008-03-31 4.44% $3.00 Million $67.63 Million -89.08pp
2007-03-31 93.52% $66.10 Million $70.69 Million -6.33pp
2006-03-31 99.84% $65.83 Million $65.93 Million --
pp = percentage points

About India Globalization Capital Inc

NYSE MKT:IGC USA Biotechnology
Market Cap
$27.56 Million
Market Cap Rank
#24227 Global
#5193 in USA
Share Price
$0.29
Change (1 day)
+0.38%
52-Week Range
$0.25 - $0.43
All Time High
$13.00
About

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatm… Read more